Log In
BCIQ
Print this Print this
 

X2

  Manage Alerts
Collapse Summary General Information
Company Emergent BioSolutions Inc.
DescriptionFusion of CTLA4 and IL10
Molecular Target CD80 (B7-1) ; Interleukin-10 (IL-10) receptor
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune disorders
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today